News and Publications

Sorrento’s and Yuhan’s Joint Venture, ImmuneOncia, receives Approval to begin clinical trial of Anti-PD-L1 Monoclonal Antibody in South Korea

Effective February 5th, 2018, Yuhan Corporation (KRX:000100.KS) (Yuhan) and Sorrento Therapeutics, Inc. (Nasdaq:SRNE) (Sorrento) announce that the South Korean Ministry of Food and Drug Safety (MFDS) has approved ImmuneOncia Therapeutics' (51% Yuhan/49% Sorrento joint venture [...]

By | 2018/03/07|Categories: News and Publications|0 Comments

The March 2018 edition of BioPharma Dealmakers

Spotlight on oncology: a trend analysis of the value, volume and development stage of deals shaping the current landscape. https://biopharmadealmakers.nature.com/users/61237-immuneoncia-therapeutics-inc/posts/30982-novel-immunotherapies-to-combine-with-pd-1-pd-l1-treatment    

By | 2018/03/07|Categories: News and Publications|0 Comments

A PD-L1 Latecomer Hoping To Break Into The Market

https://scrip.pharmaintelligence.informa.com/SC099801/ImmuneOncia-A-PDL1-Latecomer-Hoping-To-Break-Into-The-Market

By | 2017/11/20|Categories: News and Publications|0 Comments

ImmuneOncia “First anti-PD-L1 immunotherapy drug in Korea, clinical phase next year”

ImmuneOncia “First anti-PD-L1 immunotherapy drug in Korea, clinical phase next year” Yuhan-Sorrento joint venture company, fastest development in Korea.. “Later to expedite the development of ‘macrophage-activating anti-CD47 antibody’” “We plan to apply anti-PD-L1 ‘IMC-001’ antibody [...]

By | 2017/09/04|Categories: News and Publications|0 Comments

Yuhan Corporation And Sorrento Therapeutics Form Joint Venture Company – ImmuneOncia

SAN DIEGO and SEOUL, South Korea, March 2, 2016 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), an antibody-centric, clinical-stage biopharmaceutical company developing new treatments for cancer and other unmet medical needs, and Yuhan Corporation [...]

By | 2017/02/21|Categories: News and Publications|0 Comments